“Echoing a common refrain in medtech these days, the message from Boston’s investor day was that stabilizing core markets and a concerted effort to diversify away from these markets (both products and geographies) will drive better growth. Margins will expand and BSX will slowly return to mid-single-digit sales growth and double-digit earnings. Despite the risks in the outlook it seems already priced into the stock so we stay at Hold.,” Jefferies Group’s analyst wrote.
Boston Scientific traded down 0.53% on Wednesday, hitting $7.49. Boston Scientific has a 1-year low of $4.79 and a 1-year high of $7.73. The stock’s 50-day moving average is currently $6.. The company’s market cap is $10.154 billion.
Several other analysts have also recently commented on the stock. Analysts at RBC Capital reiterated an outperform rating on shares of Boston Scientific in a research note to investors on Wednesday. They now have a $8.00 price target on the stock. Separately, analysts at Deutsche Bank reiterated a hold rating on shares of Boston Scientific in a research note to investors on Wednesday. They now have a $7.20 price target on the stock, up previously from $6.70. Finally, analysts at Stifel Nicolaus raised their price target on shares of Boston Scientific from $8.00 to $9.00 in a research note to investors on Wednesday. They now have a buy rating on the stock.
Eight equities research analysts have rated the stock with a buy rating, eighteen have given a hold rating, and one has given a sell rating to the stock. The company currently has an average rating of – and a consensus price target of $7.65.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.